This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04944/identifier/pubchem-compound/
n11http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB04944/identifier/pubchem-substance/
n5http://linked.opendata.cz/resource/drugbank/drug/DB04944/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04944/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04944
rdf:type
n3:Drug
n3:description
Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
n3:generalReferences
# Dixon R, Fujitaki J, Sandoval T, Kisicki J: Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol. 1993 Oct;33(10):955-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8227467 # Menasche P, Jamieson WR, Flameng W, Davies MK: Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):1096-106. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7475138 # Nawarskas JJ: Acadesine: a unique cardioprotective agent for myocardial ischemia. Heart Dis. 1999 Sep-Oct;1(4):255-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11720632 # Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J: Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003 May 1;101(9):3674-80. Epub 2003 Jan 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12522004
n3:group
investigational
n3:halfLife
1 week
n3:indication
Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.
owl:sameAs
n11:DB04944
dcterms:title
Acadesine
adms:identifier
n5:DB04944 n6:17513 n8:16560 n9:14774569
n3:mechanismOfAction
The mechanism by which acadesine selectively kills B-cells is not yet fully elucidated. The action of acadesine does not require the tumour suppressor protein p53 like other treatments. This is important, as p53 is often missing or defective in cancerous B-cells. Studies have shown acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
n3:synonym
AICA-riboside
n3:proteinBinding
Negligible (approximately 1%)
n3:IUPAC-Name
n7:271B604E-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B6054-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B6053-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B6050-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B6051-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B6052-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B604C-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B604A-363D-11E5-9242-09173F13E4C5 n7:271B604D-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B604B-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:C01EB13
n3:H-Bond-Acceptor-Count
n7:271B605A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B605B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B6055-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B6056-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B6058-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B6057-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B6059-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
2627-69-2
n3:category
n3:Bioavailability
n7:271B6060-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B6062-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B6063-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B6064-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B605F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B605E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B6061-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B604F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B605C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B605D-363D-11E5-9242-09173F13E4C5